Affordable Access

deepdyve-link
Publisher Website

The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making.

Authors
  • Wang, Michael1
  • Negrier, Claude2
  • Driessler, Frank3
  • Goodman, Clifford4
  • Skinner, Mark W5, 6
  • 1 University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • 2 National Reference Center for Haemophilia, Louis Pradel Cardiology Hospital, University of Lyon, Lyon, France. , (France)
  • 3 Bayer, Basel, Switzerland. , (Switzerland)
  • 4 The Lewin Group, Falls Church, VA, USA.
  • 5 Institute for Policy Advancement Ltd, Washington, DC, USA.
  • 6 McMaster University, Hamilton, ON, Canada. , (Canada)
Type
Published Article
Journal
Patient Preference and Adherence
Publisher
Dove Medical Press
Publication Date
Jan 01, 2022
Volume
16
Pages
1439–1447
Identifiers
DOI: 10.2147/PPA.S355627
PMID: 35707346
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The anticipated emergence of hemophilia gene therapy will present people with hemophilia (PWH) and treating clinicians with increasingly complex treatment options. It will be critical that PWH and their families be empowered to participate fully in decision-making through transparent communication and the development of targeted educational resources. The Council of Hemophilia Community (CHC) convened across a series of roundtable meetings to define the patient journey for hemophilia gene therapy, and to develop a question-and-answer style resource to guide discussion between healthcare professionals (HCPs) and their patients. Patient groups were also consulted during the development of this tool. The CHC defined 5 key stages in the hemophilia gene therapy patient journey: pre-gene therapy (information-seeking and decision-making), treatment initiation, short- and long-term post-gene therapy follow-up. PWH will have different questions and concerns at each stage of their journey, which should be discussed with their HCP to aid decision-making. The resulting patient journey infographic and Q&A resource (see Supplementary Materials) has been developed for HCPs and PWH to provide a novel and practical roadmap of key issues and considerations throughout all stages. These resources support a collaborative, patient-centric, shared decision-making approach to inform treatment decision discussions between HCPs and PWH. The value of such discussions will be influenced by the language adopted; health literacy is a particularly important consideration, and these discussions should be accessible and tailored to PWH. HCPs and PWH can benefit from awareness of the common questions and uncertainties as they progress together along the patient journey. While the contents of this article are specific to hemophilia gene therapy, the concepts developed here could be adapted to aid patients in other disease states. © 2022 Wang et al.

Report this publication

Statistics

Seen <100 times